Metabolic/Obesity Phase 3 Deal Benchmarks — China (2026)
Median upfront of $148M with total deal values reaching $685M in China territory.
Median Upfront
$148M
Total Deal Value
$548M
Royalty Range
9.8%–15.9%
Territory Multiplier
0.12x
Understanding Metabolic/Obesity Deal Benchmarks at Phase 3
Phase 3 Metabolic/Obesity licensing deals in China territory command a median upfront payment of $148M, with values ranging from $96M at the low end to $192M for premium assets. These benchmarks reflect the risk-adjusted value of clinical-stage assets in the metabolic/obesity therapeutic area, where development costs, competitive dynamics, and market potential all factor into deal pricing.
Full Market Analysis
Detailed deal economics, territory impact analysis, and royalty structure breakdown.
We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.
7-day money-back guarantee · Cancel anytime
Full Benchmark Data
Full Benchmark Table
Low, median, and high ranges for upfront payments, total deal values, and royalty rates.
We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.
7-day money-back guarantee · Cancel anytime
Comparable Deals
See All Comparable Deals
View 0 comparable Metabolic/Obesity transactions with upfront payments, total values, and deal structures.
We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.
7-day money-back guarantee · Cancel anytime
Frequently Asked Questions
What is the average upfront payment for Phase 3 Metabolic/Obesity deals in China territory?
More Expert Insights
Territory impact analysis, royalty negotiation strategies, and deal structure guidance.
We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.
7-day money-back guarantee · Cancel anytime
Related Benchmarks
$9M upfront
Metabolic/Obesity · Preclinical · China
$27M upfront
Metabolic/Obesity · Phase 1 · China
$71M upfront
Metabolic/Obesity · Phase 2 · China
$418M upfront
Metabolic/Obesity · Approved · China
$87M upfront
Oncology · Phase 3 · China
$62M upfront
Neurology/CNS · Phase 3 · China
$108M upfront
Immunology · Phase 3 · China
$1.2B upfront
Metabolic/Obesity · Phase 3 · Global
Run Your Own Benchmark
These benchmarks are starting points. Get a customized valuation for your specific asset, indication, and deal structure.
Open Deal CalculatorCite This Data
Ambrosia Ventures. (2026). Metabolic/Obesity Phase 3 Deal Benchmarks — China (2026). Retrieved from https://calculator.ambrosiaventures.co/data/metabolic-phase-3-deals-china
<a href="https://calculator.ambrosiaventures.co/data/metabolic-phase-3-deals-china">Metabolic/Obesity Phase 3 Deal Benchmarks — China (2026)</a> — Ambrosia Ventures (2026)
<iframe src="https://calculator.ambrosiaventures.co/api/embed/chart?type=phase-upfront&ta=metabolic&theme=light" width="600" height="400" frameborder="0" style="border:1px solid #e2e8f0;border-radius:12px;"></iframe>
Data sourced from 1,900+ verified biopharma transactions. Updated monthly.